Dexter Yan

Shanghai Shi

Senior Reporter at Citeline

Senior Reporter at The Pink Sheet

Senior Reporter at Scrip

Featured in: Favicon

informa.com (+3) Favicon

citeline.com Favicon

invivo.citeline.com

Articles

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

1 week ago | insights.citeline.com | Dexter Yan

Strong Data For CARsgen’s CAR-T In Late-Line Gastric CancerSurvival Benefits Demonstrated In the world’s first confirmatory randomized controlled trial of any CAR-T therapies in solid tumors, CARsgen’s satricabtagene autoleucel, a Claudin 18.2-targeting chimeric antigen receptor (CAR) T-cell candidate, reduced the risks of death or disease progression by 63% in certain Chinese patients with gastric or gastroesophageal junction (G/GEJ) cancer.
Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

2 weeks ago | insights.citeline.com | Dexter Yan

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo PushPfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn. 3SBio's bispecific antibody SSGJ-707 meets Pfizer's quest for another immuno-oncology therapy to assess in combination with its in-house ADCs. (Shutterstock)
Hengrui Set For Biggest Biopharma IPO So Far This Year

3 weeks ago | insights.citeline.com | Dexter Yan

Hengrui Set For Biggest Biopharma IPO So Far This YearHong Kong Listing To Raise Up To $1.27bnJiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions. Hengrui to gross up to $1.27bn from initial public offering in Hong Kong SAR • Source: Shutterstock: stavklem
China Biopharma Podcast - 14 May 2025 (Chinese Language)

3 weeks ago | insights.citeline.com | Dexter Yan |Xu Hu

China Biopharma Podcast - 14 May 2025 (Chinese Language)Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage. join or China-based editors Dexter Yan and Xu Hu in their latest Chinese language podcast • Source: Citeline/Shutterstock
Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

3 weeks ago | insights.citeline.com | Dexter Yan

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPFNew Results Released In IPO FilingInSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong. InSilico racing against global competitors for disease-modifying therapy for idiopathic pulmonary fibrosis. • Source: Shutterstock
Chinese Vaccine Makers Turn To Emerging Markets

4 weeks ago | insights.citeline.com | Dexter Yan

Chinese Vaccine Makers Turn To Emerging Markets Domestic Slump Continues Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales. Chinese vaccine makers are increasingly looking to the emerging markets for the sales expanison of novel products. (Shutterstock)
Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

1 month ago | insights.citeline.com | Dexter Yan

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal AssetsEarly Oncology Programs Progressing Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip. Zai Lab is now on the runway for the self-discovery of first-in-class molecules. (Shutterstock)
Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

1 month ago | insights.citeline.com | Dexter Yan

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative ReactionsFrom HARMONi-2 Vs Keytruda In NSCLCAkeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

1 month ago | insights.citeline.com | Dexter Yan

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US DataAkeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients. Nasopharyngeal carcinoma is a rare form of head and neck cancer in western populations. (Shutterstock)
CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

1 month ago | insights.citeline.com | Dexter Yan

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE FundingsOverall Fundraising Still Muted Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity. VC and PE-backed fundings for Chinese biotechs remained lukewarm over the period from February to April. • Source: Shutterstock